How is Keppra (levetiracetam) level monitored and what is the therapeutic range?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Keppra (levetiracetam) levels are not routinely monitored in clinical practice as there is no well-established therapeutic range that correlates with efficacy or toxicity. Unlike many other antiepileptic drugs, levetiracetam has predictable pharmacokinetics, minimal protein binding, and few drug interactions, making therapeutic drug monitoring generally unnecessary for most patients 1. When monitoring is performed in specific situations (such as pregnancy, renal impairment, or suspected non-compliance), reference ranges of 12-46 μg/mL (70-270 μmol/L) are sometimes used, though these are not standardized across laboratories.

Key Points to Consider

  • Levetiracetam dosing is typically based on clinical response and tolerability rather than serum concentrations.
  • The medication is primarily eliminated unchanged through the kidneys, so dose adjustments are needed in patients with renal impairment 1.
  • Side effects like somnolence, dizziness, and behavioral changes can occur regardless of serum concentration, and clinicians should monitor for these symptoms while adjusting dosage based on seizure control rather than blood levels.
  • If monitoring is deemed necessary, trough levels (just before the next dose) provide the most consistent measurements. It's worth noting that the most recent study 1 from 2024 does not provide specific guidance on monitoring Keppra levels, but it does emphasize the importance of early treatment and cessation of status epilepticus to reduce morbidity and mortality. Therefore, the focus should be on clinical response and tolerability rather than serum concentrations.

From the Research

Measuring Keppra Levels

To measure Keppra (levetiracetam) levels, blood tests are typically used to determine the concentration of the drug in the blood.

  • The therapeutic range of levetiracetam is generally considered to be between 12-46 μg/mL 2.
  • Blood levetiracetam concentration can be affected by factors such as age and renal function, with older patients and those with renal dysfunction tend to have higher blood concentrations 2.
  • However, the rates of adverse reactions are not increased in these patients, suggesting that levetiracetam can be used effectively and safely without dose adjustment using blood concentration monitoring 2.

Therapeutic Range

The therapeutic range of levetiracetam is the range of blood concentrations at which the drug is effective in controlling seizures while minimizing adverse effects.

  • The therapeutic range of levetiracetam is generally considered to be between 12-46 μg/mL 2.
  • Levetiracetam has been shown to be effective in controlling seizures in patients with epilepsy, with a significant reduction in seizure frequency compared to placebo 3, 4, 5.
  • The drug has a favorable pharmacokinetic profile, with rapid and complete absorption, high oral bioavailability, and minimal metabolism, making it a useful treatment option for patients with epilepsy 3, 4, 5.

Monitoring Keppra Levels

Monitoring Keppra levels is important to ensure that the drug is effective in controlling seizures while minimizing adverse effects.

  • Blood tests can be used to measure the concentration of levetiracetam in the blood, and the results can be used to adjust the dose as needed 2.
  • The combination of levetiracetam with other antiepileptic drugs does not affect blood levetiracetam concentrations, and levetiracetam use does not significantly affect blood concentrations of concomitantly used antiepileptic drugs 2.
  • Levetiracetam may be used effectively and safely without dose adjustment using blood concentration monitoring even when administered in combination with other antiepileptics for patients with epilepsy 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Levetiracetam in the treatment of epilepsy.

Neuropsychiatric disease and treatment, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.